V
Viktor Wette
Researcher at Medical University of Vienna
Publications - 27
Citations - 1437
Viktor Wette is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 9, co-authored 22 publications receiving 1151 citations.
Papers
More filters
Journal ArticleDOI
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo- controlled trial
Michael Gnant,Georg Pfeiler,Peter Dubsky,Michael Hubalek,Richard Greil,Raimund Jakesz,Viktor Wette,Marija Balic,Ferdinand Haslbauer,Elisabeth Melbinger,Vesna Bjelic-Radisic,Silvia Artner-Matuschek,Florian Fitzal,Christian Marth,Paul Sevelda,Brigitte Mlineritsch,Günther G. Steger,Diether Manfreda,Ruth Exner,Daniel Egle,Jonas Bergh,Franz Kainberger,Susan Talbot,Douglas Warner,Christian Fesl,Christian F. Singer +25 more
TL;DR: Adjuvant denosumab 60 mg twice per year reduces the risk of clinical fractures in postmenopausal women with breast cancer receiving aromatase inhibitors, and can be administered without added toxicity.
Journal ArticleDOI
Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5
Raimund Jakesz,Hubert Hausmaninger,Ernst Kubista,Michael Gnant,Christian Menzel,Thomas Bauernhofer,Michael Seifert,Karin Haider,Brigitte Mlineritsch,P. Steindorfer,Werner Kwasny,Michael A. Fridrik,Guenther G. Steger,Viktor Wette,Hellmut Samonigg +14 more
TL;DR: Overall, the data suggest that the goserelin-tamoxifen combination is significantly more effective than CMF in the adjuvant treatment of premenopausal patients with stage I and II breast cancer.
Journal ArticleDOI
Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
Michael Gnant,Brigitte Mlineritsch,Herbert Stoeger,G. Luschin-Ebengreuth,Michael Knauer,Martin Moik,Raimund Jakesz,Michael Seifert,Susanne Taucher,Vesna Bjelic-Radisic,Marija Balic,Holger Eidtmann,Wolfgang Eiermann,Günther G. Steger,Werner Kwasny,Peter Dubsky,U Selim,Florian Fitzal,Gerhard Hochreiner,Viktor Wette,Paul Sevelda,Ferdinand Ploner,Rupert Bartsch,Christian Fesl,Richard Greil +24 more
TL;DR: The final results from ABCSG 12 suggest that twice-yearly ZOL enhances the efficacy of adjuvant endocrine treatment, and this benefit is maintained long-term.
Journal ArticleDOI
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
Michael Gnant,Georg Pfeiler,Günther G. Steger,Daniel Egle,Richard Greil,Florian Fitzal,Viktor Wette,Marija Balic,Ferdinand Haslbauer,E. Melbinger-Zeinitzer,Vesna Bjelic-Radisic,Raimund Jakesz,Christian Marth,Paul Sevelda,Brigitte Mlineritsch,Ruth Exner,Christian Fesl,Sophie Frantal,Christian F. Singer,Austrian Breast +19 more
TL;DR: Results from the ABCSG-18 trial showed that use of denosumab as an adjuvant to aromatase inhibitor therapy significantly reduced clinical fractures.
Journal ArticleDOI
Randomized Trial of Tamoxifen Versus Tamoxifen Plus Aminoglutethimide as Adjuvant Treatment in Postmenopausal Breast Cancer Patients With Hormone Receptor-Positive Disease: Austrian Breast and Colorectal Cancer Study Group Trial 6
Marianne Schmid,Raimund Jakesz,Hellmut Samonigg,Ernst Kubista,Michael Gnant,Christian Menzel,Michael Seifert,Karin Haider,Susanne Taucher,Brigitte Mlineritsch,P. Steindorfer,Werner Kwasny,Michael Stierer,Christoph Tausch,Michael A. Fridrik,Viktor Wette,Günther G. Steger,Hubert Hausmaninger +17 more
TL;DR: Aminoglutethimide given for 2 years in addition to tamoxifen for 5 years does not improve the prognosis of postmenopausal patients with receptor-positive, lymph nodes-negative or lymph node-positive breast cancer.